NasdaqGS:AMRXPharmaceuticals
How Investors May Respond To Amneal Pharmaceuticals (AMRX) Expanding Its Iohexol Generic Portfolio Across OMNIPAQUE Formats
Amneal Pharmaceuticals recently received U.S. FDA approval for additional strengths and vial sizes of its iohexol injection, a widely used radiographic contrast agent, expanding on its previously approved 300 mg iodine/mL 100 mL vials.
By launching the first generic versions referencing OMNIPAQUE across these presentations, Amneal aims for its broadened iohexol portfolio to cover most U.S. demand while offering providers greater flexibility and supply options in imaging procedures.
We’ll now...